Molecular pathogenesis of Hodgkin's lymphoma

Journal of Clinical Oncology

Volumn 23, Issue 26, 2005, Pages 6379-6386

  Re, Daniel ^a   Küppers, Ralf ^a   Diehl, Volker ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD15 ANTIGEN; CD20 ANTIGEN; CD30 ANTIGEN; CD40 LIGAND; CHEMOKINE; CYTOKINE; FAS ANTIGEN; FASCIN; FLICE INHIBITORY PROTEIN; GELATINASE A; JANUS KINASE 2; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN MDM2; SYNDECAN 1; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSCRIPTION FACTOR PAX5; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; X LINKED INHIBITOR OF APOPTOSIS; CYTOKINE RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR;

APOPTOSIS; B CELL LYMPHOMA; CANCER CELL; CELL INFILTRATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE REARRANGEMENT; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; HODGKIN DISEASE; HUMAN; IMMUNOPHENOTYPING; NONHODGKIN LYMPHOMA; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; REED STERNBERG CELL; REVIEW; COMPARATIVE STUDY; FEMALE; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; HOSPITALIZATION; MALE; METABOLISM; PATHOPHYSIOLOGY; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HODGKIN DISEASE; HUMANS; MALE; PHENOTYPE; PROGNOSIS; RECEPTORS, CYTOKINE; RECEPTORS, TUMOR NECROSIS FACTOR; REED-STERNBERG CELLS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 27244442734     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.55.013     Document Type: Review

References (79)

1. Pileri SA, Ascani S, Leoncini L, et al: Hodgkin's lymphoma: The pathologist's viewpoint. J Clin Pathol 55:162-176, 2002
2. Küppers R: Molecular biology of Hodgkin's lymphoma. Adv Cancer Res 84:277-312, 2002
3. Küppers R, Rajewsky K, Zhao M, et al: Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci USA 91:10962-10966, 1994
4. Kanzler H, Küppers R, Hansmann ML, et al: Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med 184:1495-1505, 1996
5. Marafioti T, Hummel M, Foss HD, et al: Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood 95:1443-1450, 2000
6. Küppers R, Zhao M, Hansmann ML, et al: Tracing B cell development in human germinal centres by molecular analysis of single cells picked from histological sections. EMBO J 12:4955-4967, 1993
7. Bräuninger A, Hansmann ML, Strickler JG, et al: Identification of common germinal-center B-cell precursors in two patients with both Hodgkin's disease and non-Hodgkin's lymphoma. N Engl J Med 340:1239-1247, 1999
8. Marafioti T, Hummel M, Anagnostopoulos I, et al: Classical Hodgkin's disease and follicular lymphoma originating from the same germinal center B cell. J Clin Oncol 17:3804-3809, 1999
9. Müschen M, Rajewsky K, Bräuninger A, et al: Rare occurrence of classical Hodgkin's disease as a T cell lymphoma. J Exp Med 191:387-394, 2000
10. Seitz V, Hummel M, Marafioti T, et al: Detection of clonal T-cell receptor gamma-chain gene rearrangements in Reed-Sternberg cells of classic Hodgkin disease. Blood 95:3020-3024, 2000
11. Chan WC: Cellular origin of nodular lymphocyte-predominant Hodgkin's lymphoma: Immunophenotypic and molecular studies. Semin Hematol 36:242-252, 1999
12. Stein H, Marafioti T, Foss HD, et al: Downregulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription. Blood 97:496-501, 2001
13. Carbone A, Gloghini A, Gaidano G, et al: Expression status of BCL-6 and syndecan-1 identifies distinct histogenetic subtypes of Hodgkin's disease Blood 92:2220-2228, 1998
14. Greiner A, Tobollik S, Buettner M, et al: Differential expression of activation-induced cytidine deaminase (AID) in nodular lymphocyte-predominant and classical Hodgkin lymphoma. J Pathol 205:541-547, 2005
15. Bräeuninger A, Küppers R, Strickler JG, et al: Hodgkin and Reed-Sternberg cells in lymphocyte predominant Hodgkin disease represent clonal populations of germinal center-derived tumor B cells. Proc Natl Acad Sci U S A 94:9337-9342, 1997
16. Marafioti T, Hummel M, Anagnostopoulos I, et al: Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells. N Engl J Med 337:453-458, 1997
17. Ohno T, Stribley JA, Wu G, et al: Clonality in nodular lymphocyte-predominant Hodgkin's disease. N Engl J Med 337:459-465, 1997
18. Schwering I, Bräuninger A, Klein U, et al: Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 101:1505-1512, 2003
19. Re D, Müschen M, Ahmadi T, et al: Oct-2 and Bob-1 deficiency in Hodgkin and Reed Sternberg cells. Cancer Res 61:2080-2084, 2001
20. Ushmorov A, Ritz O, Hummel M, et al: Epigeneticsilencing of the immunoglobulin heavy-chain gene in classical Hodgkin lymphoma-derived cell lines contributes to the loss of immunoglobulin expression. Blood 104:3326-3334, 2004
21. Jundt F, Anagnostopoulos I, Förster R, et al: Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood 99:3398-3403, 2002
22. Weber-Matthiesen K, Deerberg J, Poetsch M, et al: Numerical chromosome aberrations are present within the CD30+ Hodgkin and Reed-Sternberg cells in 100% of analyzed cases of Hodgkin's disease. Blood 86:1464-1468, 1995
23. Gravel S, Delsol G, Al Saati T: Single-cell analysis of the t(14;18)(q32;q21) chromosomal translocation in Hodgkin's disease demonstrates the absence of this translocation in neoplastic Hodgkin and Reed-Sternberg cells. Blood 91:2866-2874, 1998
24. Martin-Subero JI, Renne C, Grohmann S, et al: Chromosomal rearrangements affecting the BCL6, MYC and MALT1 loci are rare events in classical Hodgkin lymphoma. Eur J Hematol 73:B23, 2004 (suppl 65)
25. Thomas RK, Schmitz R, Harttrampf AC, et al: Apoptosis-resistant phenotype of classical Hodgkin's lymphoma is not mediated by somatic mutations within genes encoding for members of the death-inducing singalmg complex (DISC). Leukemia 19:1079-1082, 2005
26. Cabannes E, Khan G, Aillet F, et al: Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for Ikappa-Balpha. Oncogene 18:3063-3070, 1999
27. Jungnickel B, Staratschek-Jox A, Brauninger A, et al: Clonal deleterious mutations in the IkappaBalpha gene in the malignant cells in Hodgkin's lymphoma. J Exp Med 191:395-402, 2000
28. Emmerich F, Meiser M, Hummel M, et al: Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells. Blood 94:3129-3134, 1999
29. Emmerich F, Theurich S, Hummel M, et al: Inactivating I kappa B epsilon mutations in Hodgkin/Reed-Sternberg cells. J Pathol 201:413-420, 2003
30. Martin-Subero JI, Gesk S, Harder L, et al: Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma. Blood 99:1474-1477, 2002
31. Joos S, Küpper M, Ohl S, et al: Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Res 60:549-552, 2000
32. Küpper M, Joos S, von Bonin F, et al: MDM2 gene amplification and lack of p53 point mutations in Hodgkin and Reed-Sternberg cells: Results from single-cell polymerase chain reaction and molecular cytogenetic studies. Br J Haematol 112:768-775, 2001
33. Caldwell RG, Wilson JB, Anderson SJ, et al: Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 9:405-411, 1998
34. Casola S, Otipoby KL, Alimzhanov M, et al: B cell receptor signal strength determines B cell fate. Nat Immunol 5:317-327, 2004
35. Wlodarska I, Nooyen P, Maes B, et al: Frequent occurrence of BCL6 rearrangements in nodular lymphocyte predominance Hodgkin lymphoma but not in classical Hodgkin lymphoma. Blood 101:706-710, 2003
36. Green DR: Overview: Apoptotic signaling pathways in the immune system. Immunol Rev 193:5-9, 2003
37. Chhanabhai M, Krajewski S, Krajewska M, et al: Immunohistochemical analysis of interleukin-1 beta-converting enzyme/Ced-3 family protease, CPP32/Yama/Caspase-3, in Hodgkin's disease. Blood 90:2451-2455, 1997
38. Izban KF, Wrone-Smith T, Hsi ED, et al: Characterization of the interleukin-1 beta-converting enzyme/ced-3-family protease, caspase-3/ CPP32, in Hodgkin's disease: Lack of caspase-3 expression in nodular lymphocyte predominance Hodgkin's disease. Am J Pathol 154:1439-1447, 1999
39. Thomas RK, Kallenborn A, Wickenhauser C, et al: Constitutive expression of c-FLIP in Hodgkin and Reed-Sternberg cells. Am J Pathol 160:1521-1528, 2002
40. Maggio EM, Van Den Berg A, de Jong D, et al: Low frequency of FAS mutations in Reed-Sternberg cells of Hodgkin's lymphoma. Am J Pathol 162:29-35, 2003
41. Mathas S, Lietz A, Anagnostopoulos I, et al: c-FLIP mediates resistance of Hodgkin/ Reed-Sternberg cells to death receptor-induced apoptosis. J Exp Med 199:1041-1052, 2004
42. Dutton A, O'Neil JD, Milner AE, et al: Expression of the cellular FLICE-inhibitory protein (c-FLIP) protects Hodgkin's lymphoma cells from autonomous Fas-mediated death. Proc Natl Acad Sci USA 101:6611-6616, 2004
43. Kashkar H, Haefs C, Shin H, et al: XIAP-mediated caspase inhibition in Hodgkin's lymphoma-derived B cells. J Exp Med 198:341-347, 2003
44. Müschen M, Re D, Brauninger A, et al: Somatic mutations of the CD95 gene in Hodgkin and Reed-Sternberg cells. Cancer Res 60:5640-5643, 2000
45. Straus SE, Jaffe ES, Puck JM, et al: The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood 98:194-200, 2001
46. Kashkar H, Krönke M, Jurgensmeier JM: Defective Bax activation in Hodgkin B-cell lines confers resistance to staurosporine-induced apoptosis. Cell Death Differ 9:750-757, 2002
47. Zheng B, Georgakis GV, Li Y, et al: Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors. Clin Cancer Res 10:3207-3215, 2004
48. Garcia JF, Camacho FI, Morente M, et al: Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: Analyses using tissue microarrays. Blood 101:681-689, 2003
49. Zheng B, Fiumara P, Li YV, et al: MEK/ERK pathway is aberrantly active in Hodgkin disease: A signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. Blood 102:1019-1027, 2003
50. Mathas S, Hinz M, Anagnostopoulos I, et al: Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. EMBO J 21:4104-4113, 2002
51. Georgakis GV, Li Y, Rassidakis GZ, et al: Differential effects of three small molecules blocking phosphatidylinositol-3 kinase or AKT in Hodgkin disease cell lines: Induction of apoptosis and cell cycle arrest. Blood 104:125a, 2004 (abstr 428)
52. Nagel S, Scherr M, Quentmeier H, et al: HLXB9 activates IL6 in Hodgkin Lymphoma cell lines and is regulated by PI3K signalling involving E2F3. Leukemia 19:841-846, 2005
53. Marshall NA, Christie LE, Munro LR, et al: Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 103:1755-1762, 2004
54. Hsu SM, Lin J, Xie SS, et al: Abundant expression of transforming growth factor-beta 1 and -beta 2 by Hodgkin's Reed-Sternberg cells and by reactive T lymphocytes in Hodgkin's disease. Hum Pathol 24:249-255, 1993
55. Samoszuk M, Nansen L: Detection of interleukin-5 messenger RNA in Reed-Sternberg cells of Hodgkin's disease with eosinophilia. Blood 75:13-16, 1990
56. Jundt F, Anagnostopoulos I, Bommert K, et al: Hodgkin/Reed-Sternberg cells induce fibroblasts to secrete eotaxin, a potent chemoattractant for T cells and eosinophils. Blood 94:2065-2071, 1999
57. Teruya-Feldstein J, Jaffe ES, Burd PR, et al: Differential chemokine expression in tissues involved by Hodgkin's disease: Direct correlation of eotaxin expression and tissue eosinophilia. Blood 93:2463-2470, 1999
58. von Wasielewski S, Franklin J, Fischer R, et al: Nodular sclerosing Hodgkin disease: New grading predicts prognosis in intermediate and advanced stages. Blood 101:4063-4069, 2003
59. Skinnider BF, Elia AJ, Gascoyne RD, et al: Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 99:618-626, 2002
60. Maggio E, van den Berg A, Diepstra A, et al: Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues. Ann Oncol 13 (Suppl1):52-56, 2002
61. Kapp U, Yeh WC, Patterson B, et al: Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. J Exp Med 189:1939-1946, 1999
62. Skinnider BF, Elia AJ, Gascoyne RD, et al: Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 97:250-255, 2001
63. Ohshima K, Akaiwa M, Umeshita R, et al: Interleukin-13 and interleukin-13 receptor in Hodgkin's disease: Possible autocrine mechanism and involvement in fibrosis. Histopathology 38:368-375, 2001
64. Trieu Y, Wen XY, Skinnider BF, et al: Soluble interleukin-13Ralpha2 decoy receptor inhibits Hodgkin's lymphoma growth in vitro and in vivo. Cancer Res 64:3271-3275, 2004
65. Herbst H, Foss HD, Samol J, et al: Frequent expression of interleukin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin's disease. Blood 87:2918-2929, 1996
66. Newcom SR, Kadin ME, Ansari AA, et al: L-428 nodular sclerosing Hodgkin's cell secretes a unique transforming growth factor-beta active at physiologic pH. J Clin Invest 82:1915-1921, 1988
67. Yoshie O, Imai T, Nomiyama H: Chemokines in immunity. Adv Immunol 78:57-110, 2001
68. Hanamoto H, Nakayama T, Miyazato H, et al: Expression of CCL28 by Reed-Sternberg cells defines a major subtype of classical Hodgkin's disease with frequent infiltration of eosinophils and/or plasma cells. Am J Pathol 164:997-1006, 2004
69. Hone R, Watanabe T, Ito K, et al: Cytoplasmic aggregation of TRAF2 and TRAF5 proteins in the Hodgkin-Reed-Sternberg cells. Am J Pathol 160:1647-1654, 2002
70. Su CC, Chiu HH, Chang CC, et al: CD30 is involved in inhibition of T-cell proliferation by Hodgkin's Reed-Sternberg cells. Cancer Res 64:2148-2152, 2004
71. Gruss HJ, Hirschstein D, Wright B, et al: Expression and function of CD40 on Hodgkin and Reed-Sternberg cells and the possible relevance for Hodgkin's disease. Blood 84:2305-2314, 1994
72. Carbone A, Gloghini A, Gruss HJ, et al: CD40 ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin's disease. Am J Pathol 147:912-922, 1995
73. Metkar SS, Naresh KN, Redkar AA, et al: CD40-ligation-mediated protection from apoptosis of a Fas-sensitive Hodgkin's-disease-derived cell line. Cancer Immunol Immunother 47:104-112, 1998
74. Fiumara P, Snell V, Li Y, et al: Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. Blood 98:2784-2790, 2001
75. Kretschmer C, Jones DB, Morrison K, et al: Tumor necrosis factor alpha and lymphotoxin production in Hodgkin's disease. Am J Pathol 137:341-351, 1990
76. Krappmann D, Emmerich F, Kordes U, et al: Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/ Reed-Sternberg cells. Oncogene 18:943-953, 1999
77. Teofili L, Di Febo AL, Pierconti F, et al: Expression of the c-met proto-oncogene and its ligand, hepatocyte growth factor, in Hodgkin disease. Blood 97:1063-1069, 2001
78. Oelmann E, Herbst H, Zuhlsdorf M, et al: Tissue inhibitor of metalloproteinases 1 is an autocrine and paracrine survival factor, with additional immune-regulatory functions, expressed by Hodgkin/Reed-Sternberg cells. Blood 99:258-267, 2002
79. Shipp MA, Ross KN, Tamayo P, et al: Diffuse large B-cell lymphoma outcome prediction by gene-expression profiting and supervised machine learning. Nat Med 8:68-74, 2002